{"symbol":"MDT","fiscalQuarter":"Q4-2026","reportDate":"2026-06-03","reportTime":"BMO","status":"upcoming","company":{"name":"Medtronic plc","sector":"Health Care","industry":"Health Care Equipment"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/MDT/earnings/Q4-2026","estimates":{"consensusEps":1.5465,"consensusRevenue":9614.54,"epsLow":1.52,"epsHigh":1.66,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Medtronic plc (MDT) is a global leader in medical technology, providing innovative solutions for chronic diseases and surgical procedures. As part of the Health Care sector, Medtronic's products are crucial for improving patient outcomes and reducing healthcare costs.","keyMetrics":[{"name":"EPS","why":"Earnings per share (EPS) is a key indicator of profitability and reflects the company's ability to generate profit for shareholders.","consensus":"$1.55"},{"name":"Revenue","why":"Revenue growth is essential for assessing the company's market position and operational efficiency, especially in a competitive healthcare landscape.","consensus":"$9.6B"}],"lastQuarterRecap":{"summary":"In Q3-2026, Medtronic reported an EPS of $1.36, slightly exceeding expectations. However, the stock reacted negatively, declining by 3.10% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Medtronic to report solid earnings this quarter, with a consensus EPS of $1.55 and revenue of $9.6 billion. The market is closely watching for any signs of growth or challenges in their product lines.","bullCase":"If Medtronic can exceed EPS expectations and show strong revenue growth, it could signal a robust recovery in demand for its medical devices, leading to increased investor confidence.","bearCase":"Conversely, if the company misses earnings estimates or provides weak guidance, it could raise concerns about its competitive position and growth prospects, leading to a further decline in stock price."},"optionsSignal":{"impliedMove":"5.32%","context":"The options market is pricing in a significant move around the earnings report, indicating heightened uncertainty among investors.","historicalAvgMove":"3.6%","richness":"rich","richnessContext":"Options price a 5.2% move but the stock has averaged only 3.6% over the last 8 quarters \u2014 setup is rich."},"earningsTrackRecord":[{"quarter":"Q3-2026","epsSurprise":"+2.10%","reaction":"-3.10%"},{"quarter":"Q2-2026","epsSurprise":"+3.66%","reaction":"+4.69%"},{"quarter":"Q1-2026","epsSurprise":"-4.26%","reaction":"-3.14%"},{"quarter":"Q4-2025","epsSurprise":"+2.73%","reaction":"-2.27%"},{"quarter":"Q3-2025","epsSurprise":"+2.43%","reaction":"-7.26%"},{"quarter":"Q2-2025","epsSurprise":"+1.20%","reaction":"-2.96%"},{"quarter":"Q1-2025","epsSurprise":"+2.76%","reaction":"+0.66%"},{"quarter":"Q4-2024","epsSurprise":"+0.76%","reaction":"-5.11%"}],"pivotalQuestions":[{"question":"Will Medtronic's Q4 EPS exceed the consensus estimate of $1.55?","whyItMatters":"A beat on EPS could indicate stronger-than-expected demand for their products and boost investor confidence."},{"question":"What guidance will management provide for revenue growth in the upcoming quarters?","whyItMatters":"Management's outlook on revenue growth is crucial for assessing the company's future performance and market position."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $1.60 or higher would confirm the bull case, indicating strong operational performance.","bearTrigger":"An EPS below $1.52 would confirm the bear case, raising concerns about the company's growth trajectory.","context":"This quarter's results are pivotal as they will reflect the company's ability to navigate market challenges and capitalize on growth opportunities."},"scenarioPlaybook":{"beatAndRaise":"If Medtronic beats expectations, history suggests a potential average move of +2.19% the next day, confirming a positive outlook.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.","miss":"A miss could lead to a decline of around -3.14%, as seen in past quarters, raising concerns about the company's performance."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Medtronic's potential for revenue growth, especially in emerging markets where demand for medical devices is increasing.","supportingPoints":["The options market is pricing a larger move than historical averages suggest, indicating potential volatility.","Recent trends in healthcare spending suggest a rebound in demand for medical technologies, which could benefit Medtronic.","The company's strong history of beating EPS estimates may not be fully reflected in current market sentiment."],"riskToConsensus":"If management provides strong guidance for revenue growth, it could significantly shift market expectations."},"whatToListenFor":["Any commentary on product demand trends in emerging markets.","Updates on new product launches and their expected impact on revenue.","Insights into cost management strategies and their effect on margins.","Details on competitive pressures and how Medtronic plans to address them.","Management's outlook on regulatory changes and their potential impact on operations."],"metaDescription":"Medtronic (MDT) reports Q4 2026 earnings June 3. Analysts expect $1.55 EPS on $9.6B revenue. Here's what to watch."}}